Clinical Trials Logo

Cancer of Gastrointestinal Tract clinical trials

View clinical trials related to Cancer of Gastrointestinal Tract.

Filter by:
  • None
  • Page 1

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

NCT ID: NCT05153304 Withdrawn - Clinical trials for Cancer of Gastrointestinal Tract

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Start date: June 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.

NCT ID: NCT04907643 Recruiting - Rectal Cancer Clinical Trials

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Start date: October 5, 2021
Phase: N/A
Study type: Interventional

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain. To address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.

NCT ID: NCT04838327 Recruiting - Clinical trials for Cancer of Gastrointestinal Tract

Rare Subtypes of Gastrointestinal Cancers

Start date: August 16, 2021
Phase:
Study type: Observational

A single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the Gastrointestinal Tract.

NCT ID: NCT04685759 Withdrawn - Clinical trials for Cancer of Gastrointestinal Tract

Exercise Regimens and Neoadjuvant Chemotherapy

Start date: April 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effectiveness of exercise therapy for patients undergoing neoadjuvant chemotherapy for primary gastrointestinal (GI) tract cancer, providing a reproducible exercise regimen designed to improve or preserve aerobic fitness, strength, and quality of life. In addition, this study will address shifts in healthcare delivery needed as a result of the coronavirus disease 2019 (COVID-19) pandemic, evaluating the effectiveness of telehealth instruction as a method for exercise therapy. The study hypotheses are: 1. To evaluate the effectiveness of exercise therapy for cancer patients undergoing neoadjuvant treatment when delivered via telehealth, as compared to an in-person setting. 2. To assess stair test instrumentation, previously validated in a healthy population, as a measure to gauge health status in cancer patients undergoing neoadjuvant treatment. 3. To assess patient satisfaction with exercise therapy when delivered via telehealth, as compared to an in-person setting.

NCT ID: NCT04426669 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Start date: May 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal (GI) Cancer.

NCT ID: NCT03538613 Withdrawn - Clinical trials for Gastrointestinal Neoplasm

Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Start date: May 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Background: The gene CISH can weaken immune cells called lymphocytes. It is found in all cells of the body but it most negatively impacts lymphocytes. This study may help people with certain cancers.Lymphocyte cells will be taken from their tumors, the CISH gene will be removed from those cells, then the cells will be returned to the person. Researchers hope this process will help the cells work better and fight the tumors. Objective: To see if cells with the CISH gene removed are safe and shrink metastatic gastrointestinal epithelial tumors. Eligibility: People 18 70 years old with metastatic gastrointestinal epithelial cancer Design: Participants will be screened with physical exam, scans, and heart, lung, blood, and urine tests. Participants will have cells collected in another protocol. They must tell their doctor of any antibiotic allergy. The cells will be changed in a lab. Participants will stop therapy 4 6 weeks before getting the cells back. Participants will have leukapheresis. Blood is sent by a needle in one arm into a machine that takes out the white blood cells. The blood is returned through a needle in the other arm. Participants will have an IV catheter inserted in their upper chest to receive medicines and the cells. Participants will stay in the hospital and: - Have chemotherapy for 1 week - Get the cells for about a half hour to a little over an hour - Get a cell growth medicine about every 8 hours for up to 12 doses - Get medicines to boost blood cells and fight side effects - Recover for 1 3 weeks. Participants will have 2 follow-up visits within 12 weeks of treatment, then a couple visits each year. They will repeat screening tests.

NCT ID: NCT01730586 Completed - Colorectal Cancer Clinical Trials

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Start date: November 2012
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied. Abraxane is designed to block cancer cells from dividing, which may cause them to die.

NCT ID: NCT01313442 Recruiting - Clinical trials for Gastrointestinal Cancer

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

Start date: March 2, 2011
Phase:
Study type: Observational

Background: - Gastrointestinal cancers can occur in the throat, stomach, gallbladder, liver, pancreas, and colon. Researchers are interested in evaluating how active the immune system is in trying to fight the cancer by studying blood and tumor tissue donated from individuals who have been diagnosed with gastrointestinal cancers. Objectives: - To collect blood and tumor samples from individuals who have been diagnosed with gastrointestinal cancers in order to study the immune system s response to the cancer. Eligibility: - Individuals at least 18 years of age who have been diagnosed with throat, stomach, gallbladder, liver, pancreatic, or colon cancer, and are scheduled to be treated at the National Institutes of Health. Design: - The study will require at least one but no more than four visits to the National Institutes of Health Clinical Center. - Participants will be screened with a physical examination and medical history, and will provide a baseline blood sample for study. - Participants will provide additional blood samples 2 and 4 months after the baseline sample, as well as a final sample at the completion of the treatment protocol. - Participants will provide tumor tissue samples only if they undergo a surgical procedure related to the treatment for their gastrointestinal cancer. - No treatment will be provided as part of this protocol.